“Blossoming” Evidence Demands For Drugs A Burden On Innovation, Pfizer Exec Says
Executive Summary
FDA and payers have “highly disparate” evidence objectives, and drug developers are struggling with how to respond, according to Pfizer VP Medical Affairs Gail Cawkwell.